Catalyst Calendar
Scope

Mon, Jul 6, 2026

1 updates
TGTX
7:30 AM

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.

Trial Start • Phase 2Trial initiation Mon, Jul 6, 2026tgtherapeutics.com

Tue, Jun 9, 2026

1 updates
TGTX
7:30 AM

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial utilizes novel sequential treatment approach designed to combine rapid symptom

Trial Results • Phase 1Results event Tue, Jun 9, 2026tgtherapeutics.com

Wed, Jun 3, 2026

1 updates

Tue, Jun 2, 2026

1 updates

Mon, Jun 1, 2026

1 updates
TGTX
7:30 AM

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease activity (NEDA-3) in treatment naïve patients supporting early use of high-efficacy

tgtherapeutics.com

Thu, May 28, 2026

1 updates

Wed, May 27, 2026

1 updates
TGTX
7:30 AM

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safety and tolerability of the consolidated first infusion were consistent with the established BRIUMVI

Trial Results • Phase 3Results event Wed, May 27, 2026tgtherapeutics.com

Tue, May 26, 2026

1 updates
TGTX
7:30 AM

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (RMS) at the 2026 Consortium of Multiple Sclerosis Centers

Presentation / Abstract • Phase 4Oral presentation Thu, May 28, 2026, 3:40 PM ETtgtherapeutics.com

Wed, May 6, 2026

1 updates

Thu, Apr 30, 2026

1 updates

Wed, Apr 22, 2026

1 updates

Wed, Apr 15, 2026

1 updates